BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-393@pharmaconomics
DTSTAMP:20260707T034521Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:BBIO PDUFA — encaleret (estimated date)
DESCRIPTION:The FDA's approval decision on encaleret for autosomal dominant hypocalcemia type 1 (ADH1) is due ~ Dec 31\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm\n\nTrack it: https://www.pharmaconomics.com/e/393
URL:https://www.pharmaconomics.com/e/393
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR